Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis

Journal of Family Practice

Volumn 51, Issue 6, 2002, Pages 530-537

  Kivitz, Alan ^a   Eisen, Glenn ^a   Zhao, William W ^a   Bevirt, Terry ^a   Recker, David P ^a  

^a PFIZER INC   (United States)

Author keywords

Cyclooxygenase 2 specific inhibitors; Nonsteroidal anti inflammatory drug; Osteoarthritis; Prostaglandin endoperoxide synthase

Indexed keywords

ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2 INHIBITOR; NAPROXEN; PLACEBO; PROSTAGLANDIN SYNTHASE; VALDECOXIB;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ENZYME INHIBITION; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; OSTEOARTHRITIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RISK ASSESSMENT; THROMBOCYTE FUNCTION; VISUAL IMPAIRMENT;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DIGESTIVE SYSTEM; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; NAPROXEN; OSTEOARTHRITIS; PAIN MEASUREMENT; SULFONAMIDES; TREATMENT OUTCOME;

EID: 0036273374     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Epidemiology of hip and knee osteoarthritis
2. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial
3. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: What can we expect?
4. The American College of Rheumatology criteria for the classification and reportings of osteoarthritis of the knee
5. A seven-day variability study of 499 patients with peripheral rheumatoid arthritis
6. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis. Subsets of responses
7. A sharper Bonferroni procedure for multiple tests of significance
8. Nonparametric confidence limits for survival probabilities and median survival time
9. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage. Influence of nitric oxide
10. Carrageenan-induced hyperalgesia is associated with increased cyclooxygenase-2 expression in spinal cord
11. Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis
12. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo
13. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis
14. A double-blind, placebo-controlled dose ranging study to evaluate the efficacy of valdecoxib, a novel COX-2 specific inhibitor, in treating the signs and symptoms of osteoarthritis of the knee
15. Risk of upper gastrointestinal bleeding and perforation associated with individual nonsteroidal anti-inflammatory drugs
16. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study
17. NSAID induced gastrointestinal complications: The ARAMIS perspective-1997. Arthritis, Rheumatism, and Aging Medical Information System
18. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis
19. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
20. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
21. Nonsteroidal anti-inflammatory drug discontinuation in patients with osteoarthritis